B-cell chronic lymphocytic leukemia (B-CLL) is characterized by the accumulation of monoclonal lymphocytes coexpressing CD19, CD5 and CD23, and low levels of surface immunoglobulins (sIg), CD79b and CD22. 1 This phenotypic feature correlates with defective signal transduction after antigen stimulation through the B-cell receptor (BCR). CD22 is a B-cell-specific transmembrane glycoprotein constituted by two polypeptide chains, CD22a and CD22b, of 130 and 140 kDa respectively, produced by alternative splicing of the CD22 gene. It is involved in the regulation of B-cell activation through BCR signaling, as well as in cell adhesion. 2 The expression pattern of CD22 is correlated with that of IgM as in CD22-deficient mice and gene-targeted mice expressing mutated CD22 molecules, B cells have decreased surface IgM expression. 3, 4 We reported that underexpression of the BCR in B-CLL cells is associated with glycosylation and folding defects of the m and CD79a chains, but not of the CD79b. 5 We investigated here the defect of CD22 surface expression in B-CLL cells by analyzing CD22a and b chains at the genetic, transcriptional and post-transcriptional level.
B cells from seven typical B-CLL patients were analyzed by flow cytometry for CD22 and IgM surface expression (Table 1a) , and compared to healthy donors. CD22 protein analysis by Western blot (Figure 1a ) showed two chains of 140 and 130 kDa in B-lymphoma cells and normal B cells (lanes 8-10 and 11, respectively), whereas the 130 kDa band was not detected in the majority of B-CLL cells (patients 1-5), or very poorly in two samples (patients 6 and 7). Following treatment of cell extracts with N-glycosidase F that cleaves all N-linked oligosaccharides, two bands at 100 and 80 kDa, respectively corresponding to the CD22b and a core proteins, appeared in control Daudi lymphoma B cells (Figure 1b, panel 1) . In contrast, the 80 kDa core protein band of CD22a was absent in B-CLL cell extracts (Figure 1b, panel 2 ). When treated with Endo-H, which cleaves only endoplasmic reticulum-localized glycoproteins (immature forms), no measurable shift of molecular mass of the CD22b chain was detected in B-CLL cell extracts (Figure 1c, panels 1-3 ), indicating that this b chain is present in a mature glycoform similar to that observed in Daudi cells and normal B cells (Figure 1c , panels 4 and 5, respectively). These results suggest that in B-CLL cells, despite the presence of a mature b chain, absence or very low level of CD22a chain may account for an incomplete CD22 molecule and may lead to low surface expression. This result is reminiscent of our previous results 5 showing that the CD79b, which is present in a mature glycoform, is very poorly expressed at the cell surface, as a consequence of poor assembly of the BCR components.
Sequencing of the CD22 gene in two patients showed a few silent or replacement mutations (Table 1b) previously described as polymorphic features of the CD22 gene. 6 However, we found a previously unreported two amino acids deletion (V and L in positions 12 and 13) in the leader peptide, which, as it was also present in normal and Daudi B cells, probably corresponds to a polymorphism not affecting membrane protein traffic and expression.
Interestingly, both CD22a and CD22b mRNA isoforms were expressed in all CLL patients, with CD22a/CD22b ratios in the CLL group very similar to those of normal or lymphoma B cells (data not shown). Hence, absence or low CD22a protein expression in B-CLL cells is the consequence of a posttranscriptional defect.
In mouse models, a defect in the CD22 molecule is strongly associated with low BCR expression. 3 This phenotype is also characteristic of B-CLL cells. In CLL, all the BCR components are synthesized, but are unable to assemble and to be transported to the cell surface because of a folding and glycosylation defect of the m and CD79a components. 5 We demonstrate here that despite the presence of normal transcripts, the CD22a chain is not detected at the protein level. Taking into account our previous results with BCR components in CLL, this could suggest the presence of a folding defect of the CD22a chain, resulting in its rapid degradation and preventing its assembly with CD22b. As the B-CLL cell has been postulated to correspond to an anergic B cell, it is presently unclear whether a dissociation of the CD22 complex, similar to that reported for the BCR, 7 could be the consequence of an anergic process. Alternatively, a mechanism of RNA interference could be proposed to explain the absence of the CD22a protein. Indeed, the presence of microRNAs has been recently described in B-CLL. 8 Although further investigations are required to better define the mechanism involved, our results provide consistent evidence indicating a defect in expression at the protein level of the CD22a isoform accounting for low CD22 surface expression. 
